

Amgen Inc.
Condensed Consolidated Statements of Income and
Reconciliation of GAAP Earnings to "Adjusted" Earnings
(In millions, except per share data)
(Unaudited)

	Three Months Ended June 30, 2010			Three Months Ended June 30, 2009		
	GAAP	Adjustments	"Adjusted"	GAAP	Adjustments	"Adjusted"
Revenues:						
Product sales.....	\$ 3,613	\$ -	\$ 3,613	\$ 3,634	\$ -	\$ 3,634
Other revenues.....	191	-	191	79	-	79
Total revenues.....	<u>3,804</u>	<u>-</u>	<u>3,804</u>	<u>3,713</u>	<u>-</u>	<u>3,713</u>
Operating expenses:						
Cost of sales (excludes amortization of certain acquired intangible assets presented below).....	553	(4) (a)	549	531	(3) (a)	527
Research and development.....	675	(16) (a)	642	693	(16) (a)	657
		(17) (b)			(17) (b)	
		(3) (f)			(3) (f)	
Selling, general and administrative.....	986	(18) (a)	968	910	(16) (a)	891
Amortization of certain acquired intangible assets.....	73	(73) (c)	-	73	(73) (c)	-
Other.....	-	-	-	49	(20) (d)	-
					(29) (f)	
Total operating expenses.....	<u>2,287</u>	<u>(128)</u>	<u>2,159</u>	<u>2,256</u>	<u>(181)</u>	<u>2,075</u>
Operating income.....	1,517	128	1,645	1,457	181	1,638
Interest expense, net.....	147	(66) (e)	81	150	(62) (e)	88
Interest and other income, net.....	94	-	94	50	-	50
Income before income taxes.....	1,464	194	1,658	1,357	243	1,600
Provision for income taxes.....	262	70 (g)	332	88	86 (h)	289
					115 (i)	
Net income.....	<u>\$ 1,202</u>	<u>\$ 124</u>	<u>\$ 1,326</u>	<u>\$ 1,269</u>	<u>\$ 42</u>	<u>\$ 1,311</u>
Earnings per share:						
Basic.....	\$ 1.25		\$ 1.38	\$ 1.25		\$ 1.29
Diluted (k).....	\$ 1.25		\$ 1.38 (a)	\$ 1.25		\$ 1.29 (a)
Average shares used in calculation of earnings per share:						
Basic.....	959		959	1,013		1,013
Diluted (k).....	964		964 (a)	1,017		1,016 (a)

(a) - (k) See explanatory notes on the following pages.

Provided July 29, 2010 as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

Amgen Inc.
Condensed Consolidated Statements of Income and
Reconciliation of GAAP Earnings to "Adjusted" Earnings
(In millions, except per share data)
(Unaudited)

	Six months ended June 30, 2010			Six months ended June 30, 2009		
	GAAP	Adjustments	"Adjusted"	GAAP	Adjustments	"Adjusted"
Revenues:						
Product sales.....	\$ 7,141	\$ -	\$ 7,141	\$ 6,872	\$ -	\$ 6,872
Other revenues.....	255	-	255	149	-	149
Total revenues.....	<u>7,396</u>	<u>-</u>	<u>7,396</u>	<u>7,021</u>	<u>-</u>	<u>7,021</u>
Cost of sales (excludes amortization of certain acquired intangible assets presented below).....	1,061	(8) (a)	1,053	1,008	(6) (a) (1) (f)	1,001
Research and development.....	1,321	(28) (a) (34) (b)	1,259	1,326	(27) (a) (34) (b) (3) (f)	1,262
Selling, general and administrative.....	1,870	(29) (a)	1,841	1,708	(26) (a) (17) (f)	1,665
Amortization of certain acquired intangible assets.....	147	(147) (c)	-	147	(147) (c)	-
Other.....	(1)	1 (d)	-	54	(20) (d) (34) (f)	-
Total operating expenses.....	<u>4,398</u>	<u>(245)</u>	<u>4,153</u>	<u>4,243</u>	<u>(315)</u>	<u>3,928</u>
Operating income.....	2,998	245	3,243	2,778	315	3,093
Interest expense, net.....	292	(131) (e)	161	297	(123) (e)	174
Interest and other income, net.....	178	-	178	108	-	108
Income before income taxes.....	2,884	376	3,260	2,589	438	3,027
Provision for income taxes.....	515	137 (g)	652	301	155 (h) 115 (i) 25 (j)	596
Net income.....	<u>\$ 2,369</u>	<u>\$ 239</u>	<u>\$ 2,608</u>	<u>\$ 2,288</u>	<u>\$ 143</u>	<u>\$ 2,431</u>
Earnings per share:						
Basic	\$ 2.44		\$ 2.69	\$ 2.24		\$ 2.38
Diluted (k)	\$ 2.43		\$ 2.67 (a)	\$ 2.23		\$ 2.37 (a)
Average shares used in calculation of earnings per share:						
Basic	970		970	1,023		1,023
Diluted (k)	976		976 (a)	1,027		1,026 (a)

(a) - (k) See explanatory notes on the following pages.

Amgen Inc.
Notes to Reconciliation of GAAP Earnings to "Adjusted" Earnings
(In millions, except per share data)
(Unaudited)

- (a) To exclude stock option expense. For the three and six months ended June 30, 2010 and 2009, the total pre-tax expense for employee stock options was \$38 million and \$65 million, respectively, and \$35 million and \$59 million, respectively.

*Adjusted" diluted EPS including the impact of stock option expense for the three and six months ended June 30, 2010 and 2009 was as follows:

	Three months ended June 30,		Six months ended June 30,	
	2010	2009	2010	2009
"Adjusted" diluted EPS, excluding stock option expense.....	\$ 1.38	\$ 1.29	\$ 2.67	\$ 2.37
Impact of stock option expense (net of tax).....	(0.04)	(0.02)	(0.05)	(0.04)
"Adjusted" diluted EPS, including stock option expense.....	<u>\$ 1.34</u>	<u>\$ 1.27</u>	<u>\$ 2.62</u>	<u>\$ 2.33</u>

- (b) To exclude the ongoing, non-cash amortization of the R&D technology intangible assets with alternative future uses acquired with the acquisitions of Abgenix, Inc. ("Abgenix") and Avidia, Inc. ("Avidia").
- (c) To exclude the ongoing, non-cash amortization of acquired product technology rights, primarily ENBREL, related to the Immunex Corporation ("Immunex") acquisition.
- (d) To exclude loss accruals or awards for legal settlements.
- (e) To exclude the incremental non-cash interest expense resulting from a change in the accounting for our convertible notes effective January 1, 2009.
- (f) To exclude the expenses associated with our restructuring plan announced in August 2007 and certain additional cost savings initiatives subsequently identified.
- (g) To reflect the tax effect of the above adjustments for 2010.
- (h) To reflect the tax effect of the above adjustments for 2009.
- (i) To exclude the income tax benefit recognized as a result of resolving certain non-routine transfer pricing issues with the Internal Revenue Service ("IRS") for prior periods.
- (j) To exclude the net tax benefit resulting from adjustments to previously established deferred taxes, primarily related to prior acquisitions and stock option expense, due to changes in California tax law effective for future periods.
- (k) The following table presents the computations for GAAP and "Adjusted" diluted earnings per share, computed under the treasury stock method. "Adjusted" earnings per share presented below excludes stock option expense:

	Three months ended June 30, 2010		Three months ended June 30, 2009	
	GAAP	"Adjusted"	GAAP	"Adjusted"
Income (Numerator):				
Net income for basic and diluted EPS.....	\$ 1,202	\$ 1,326	\$ 1,269	\$ 1,311
Shares (Denominator):				
Weighted-average shares for basic EPS.....	959	959	1,013	1,013
Effect of dilutive securities.....	5	5 (*)	4	3 (*)
Weighted-average shares for diluted EPS.....	<u>964</u>	<u>964</u>	<u>1,017</u>	<u>1,016</u>
Diluted earnings per share.....	<u>\$ 1.25</u>	<u>\$ 1.38</u>	<u>\$ 1.25</u>	<u>\$ 1.29</u>
	Six months ended June 30, 2010		Six months ended June 30, 2009	
	GAAP	"Adjusted"	GAAP	"Adjusted"
Income (Numerator):				
Net income for basic and diluted EPS.....	\$ 2,369	\$ 2,608	\$ 2,288	\$ 2,431
Shares (Denominator):				
Weighted-average shares for basic EPS.....	970	970	1,023	1,023
Effect of dilutive securities.....	6	6 (*)	4	3 (*)
Weighted-average shares for diluted EPS.....	<u>976</u>	<u>976</u>	<u>1,027</u>	<u>1,026</u>
Diluted earnings per share.....	<u>\$ 2.43</u>	<u>\$ 2.67</u>	<u>\$ 2.23</u>	<u>\$ 2.37</u>

- (*) Dilutive securities used to compute "Adjusted" diluted earnings per share for the three and six months ended June 30, 2010 and 2009 were computed under the treasury stock method assuming that we do not expense stock options.

Amgen Inc.
Product Sales Detail by Product and Geographic Region
(In millions)
(Unaudited)

	Three months ended		Six months ended	
	June 30,		June 30,	
	2010	2009	2010	2009
Aranesp® - U.S.	\$ 267	\$ 338	\$ 535	\$ 630
Aranesp® - International.....	336	355	695	689
EPOGEN® - U.S.....	657	638	1,280	1,203
Neulasta® - U.S.	643	625	1,280	1,219
NEUPOGEN® - U.S.	225	230	450	432
Neulasta® - International.....	218	206	444	389
NEUPOGEN® - International.....	88	97	179	191
Enbrel® - U.S.	819	846	1,573	1,558
Enbrel® - Canada	58	53	108	99
Sensipar® - U.S.	112	113	229	212
Sensipar® - International.....	60	54	122	103
Vectibix® - U.S.	29	24	54	49
Vectibix® - International.....	43	32	85	60
Nplate® - U.S.	32	19	60	32
Nplate® - International.....	23	4	44	6
Prolia® - U.S.	3	-	3	-
Total product sales	<u>\$ 3,613</u>	<u>\$ 3,634</u>	<u>\$ 7,141</u>	<u>\$ 6,872</u>
U.S.	\$ 2,787	\$ 2,833	\$ 5,464	\$ 5,335
International.....	<u>826 (a)</u>	<u>801</u>	<u>1,677 (b)</u>	<u>1,537</u>
Total product sales.....	<u>\$ 3,613 (a)</u>	<u>\$ 3,634</u>	<u>\$ 7,141 (b)</u>	<u>\$ 6,872</u>

(a) The change in international product sales for the three months ended June 30, 2010 was positively impacted by \$11 million due to favorable impact of foreign exchange (including \$5 million for Neulasta®/NEUPOGEN®, \$3 million for Aranesp® and \$3 million for ENBREL).

(b) The change in international product sales for the six months ended June 30, 2010 was positively impacted by \$50 million due to favorable impact of in foreign exchange (including \$21 million for Neulasta®/ NEUPOGEN®, \$19 million for Aranesp®, \$6 million for ENBREL, \$2 million for Sensipar®, \$1 million for Vectibix® and \$1 million for Nplate®).

Amgen Inc.
Condensed Consolidated Balance Sheets - GAAP
(In millions)
(Unaudited)

	<u>June 30, 2010</u>	<u>December 31, 2009</u>
Assets		
Current assets:		
Cash, cash equivalents and marketable securities.....	\$ 14,523	\$ 13,442
Trade receivables, net.....	2,208	2,109
Inventories.....	2,112	2,220
Other current assets.....	1,321	1,161
Total current assets.....	<u>20,164</u>	<u>18,932</u>
Property, plant and equipment, net.....	5,630	5,738
Intangible assets, net.....	2,421	2,567
Goodwill.....	11,334	11,335
Other assets.....	1,251	1,057
Total assets.....	<u>\$ 40,800</u>	<u>\$ 39,629</u>
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable and accrued liabilities.....	\$ 3,578	\$ 3,873
Current portion of convertible notes.....	2,414	-
Total current liabilities.....	<u>5,992</u>	<u>3,873</u>
Convertible notes.....	2,232	4,512
Other long-term debt.....	7,086	6,089
Other non-current liabilities.....	2,320	2,488
Stockholders' equity.....	23,170	22,667
Total liabilities and stockholders' equity.....	<u>\$ 40,800</u>	<u>\$ 39,629</u>
Shares outstanding.....	958	995

Amgen Inc.
Reconciliation of GAAP Debt Outstanding to "Adjusted" Debt Outstanding
(In millions)
(Unaudited)

	June 30, 2010			June 30, 2009		
	<u>GAAP</u>	<u>Adjustments for accounting standard</u>	<u>"Adjusted"</u>	<u>GAAP</u>	<u>Adjustments for accounting standard</u>	<u>"Adjusted"</u>
Total debt outstanding.....	\$ 11,732	\$ 437 (a)	\$ 12,169	\$ 11,471	\$ 699 (a)	\$ 12,170

(a) To exclude the impact of adopting an accounting standard on January 1, 2009 that changed the method of accounting for our convertible notes.



Amgen Inc.
 Reconciliation of GAAP Stockholders' Equity to "Adjusted" Stockholders' Equity
 (In millions)
 (Unaudited)

	June 30, 2010			June 30, 2009		
	GAAP	Adjustments for accounting standard	"Adjusted"	GAAP	Adjustments for accounting standard	"Adjusted"
Stockholders' equity.....	\$ 23,170	\$ (262) (a)	\$ 22,908	\$ 21,360	\$ (422) (a)	\$ 20,938

(a) To exclude the impact of adopting an accounting standard on January 1, 2009 that changed the method of accounting for our convertible notes.

Amgen Inc.
Reconciliation of GAAP Earnings Per Share Guidance to "Adjusted"
Earnings Per Share Guidance for the Year Ending December 31, 2010
(Unaudited)

On July 29, 2010, the Company reaffirmed its "Adjusted" earnings per share guidance towards the lower end of the range of \$5.05 - \$5.25, including an anticipated impact of \$200 million to \$250 million due to U.S. Health Care Reform. The following table shows a reconciliation of GAAP earnings per share (diluted) guidance to "Adjusted" earnings per share (diluted) guidance.

	<u>2010</u>
GAAP earnings per share (diluted) guidance	\$ 4.55 - \$ 4.77
Known adjustments to arrive at "Adjusted" earnings*:	
Amortization of acquired intangible assets, product technology rights..... (a)	0.19
Incremental non-cash interest expense..... (b)	0.17
Stock option expense..... (c)	0.07 - 0.09
Amortization of acquired intangible assets, R&D technology rights..... (d)	<u>0.05</u>
"Adjusted" earnings per share (diluted) guidance	<u>\$ 5.05 - \$ 5.25</u>

* The known adjustments are presented net of their related aggregate tax impact of approximately \$0.27 to \$0.28 per share.

- (a) To exclude the ongoing, non-cash amortization of acquired product technology rights, primarily ENBREL, related to the Immunex acquisition.
- (b) To exclude the incremental non-cash interest expense resulting from a change in accounting in January 2009 related to our convertible debt.
- (c) To exclude stock option expense.
- (d) To exclude the ongoing, non-cash amortization of the R&D technology intangible assets acquired with the Abgenix and Avidia acquisitions.

Amgen Inc.
Reconciliation of GAAP Tax Rate Guidance to "Adjusted"
Tax Rate Guidance for the Year Ending December 31, 2010
(Unaudited)

On July 29, 2010, the Company reaffirmed its "Adjusted" tax rate guidance range of 20.0% - 21.0%. The following table shows a reconciliation of GAAP tax rate guidance to "Adjusted" tax rate guidance.

	<u>2010</u>
GAAP tax rate guidance	17.8% - 19.0%
Tax rate effect of known adjustments discussed above.....	<u>2.0% - 2.2%</u>
"Adjusted" tax rate guidance	<u>20.0% - 21.0%</u>